Myeloid leukemia reagent kit μCaler AML MRD comprehensive solution

solutionfor researchNGS

μCaler AML MRD comprehensive solution is based on liquid-phase hybridization target enrichment technology and specifically designed for adult Acute Myeloid Leukemia (AML) MRD research. This comprehensive solution selects MRD targets that cover approximately 90% of AML cases, allowing for the analysis of various mutations, including base substitutions, insertions/deletions, and gene fusions. By combining UMI and the μCaler hybrid capture system, it achieves ultra-high detection sensitivity and can complete the entire experimental process within same day. μCaler AML Panel v1.0 is designed for detecting common mutations in adult acute myeloid leukemia. The panel covers approximately 42.5 Kb region of the genome, targeting 32 genes. It enables enrichment of various types of mutation information, including base substitutions, insertions/deletions, and gene fusions, making it suitable for MRD monitoring. Performance Precision coverage ● Reference was made to multiple databases (COSMIC & TCGA) and guidelines to select regions more likely to contain mutations. ●~90% of cases have at least one mutation, and ~60% of cases have three or more mutations (AML_OHSU_2022 cohort). ● Covers approximately 42.5 Kb of the genome, allowing detection of base substitutions, insertions/deletions, and gene fusions in 32 genes associated with AML.